Patient Background:
Mr. C is a 52-year-old male with a BMI of 37 kg/m² and a 10-year history of obesity with multiple prior attempts at sustained weight loss through calorie restriction and exercise.
Comorbidities include hypertension (amlodipine 10 mg), dyslipidemia (atorvastatin 40 mg), prediabetes (HbA1c 6.2%), and obstructive sleep apnea managed with CPAP. He is a non-smoker. Family history includes paternal myocardial infarction at age 58. He is motivated for pharmacologic intervention and has enrolled in a structured lifestyle program.
Assessment & Diagnosis:
Waist circumference: 116 cm. BP: 138/86 mmHg. Fasting glucose: 108 mg/dL. LDL-C: 118 mg/dL.…read more
He is an appropriate candidate for chronic weight management therapy. Treatment selection was guided by shared decision-making, cardiometabolic risk profile, prior weight-management history, and patient preference.
The care team initiates a once-weekly subcutaneous GLP-1 receptor agonist with gradual dose escalation over 16–20 weeks to improve tolerability.
In the STEP 1 trial (n=1,961), participants treated with semaglutide achieved a mean weight loss of 14.9% vs 2.4% with placebo at 68 weeks (p<0.001).
Common adverse effects discussed with the patient include nausea, vomiting, diarrhea, and constipation, particularly during dose escalation.
- Please provide a minimum of a 3 sentence response.
- 1.Which comorbidities support GLP-1 RA therapy in this patient?
- 2.What counseling strategies help minimize GI adverse effects during GLP-1 RA dose escalation?
Share
2: I usually discuss slow titration and occasionally adding zofran for the symptoms. Will also add fiber and miralx for the constipation
2. GERD diet, small meals, high protein, increase water intake.
I feel that counseling and preparing patients for possible side effects can help tremendously.
2. Not to over eat, monthly dosage escalation if tolerating, less acidic and spicy foods, PPI for PRN or QD use.